Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of ... - PR Newswire

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (NASDAQ: OREX) today announced that the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltrexone sustained release (SR)/bupropion SR) met its ...

Read more...

---

(Not so) weird science: Medical breakthroughs that affect our lives - Fort Worth Star-Telegram

Enough medical studies were published last year to down a small forest. Most appeared with little fanfare and faded quietly, of interest only to a small group of scientists — but a handful hit like small bombshells, overturning conventional wisdom ...

Read more...

---

A single step - Howard County Times

Getting more exercise, preferably while shedding some poundage, is probably the nation's No. 1 New Year's resolution, and a group of area volksmarchers, walkers with real commitment, made a healthy start Jan. 1 -- some even the day before -- at the ...

Read more...

---

New hope for failed obesity drug - Boston Globe

NEW YORK - Leptin, the appetite-suppressing drug that flunked tests for weight loss in people, is resurrecting hope with a study showing it worked better in mice when combined with other medicines. The research showed obese mice lost weight when ...

Read more...

---

People don't always get enough vitamin D - Reading Eagle

Vitamin D is the newest star in the nutritional firmament. Researchers say people need vitamin D for strong bones and healthy hearts, but usually aren't getting enough of it. A deficiency is being pinpointed as a risk factor for some major diseases ...

Read more...

---

Obesity-Drug Combination Works in Mice, Revives Hope for People - Bloomberg

Jan. 6 (Bloomberg) -- Leptin, the appetite-suppressing drug that flunked tests for weight loss in people, is resurrecting hope with a study showing it worked better in mice when combined with other medicines. The research showed obese mice lost ...

Read more...

---

Promedior Announces Appointment of Dominick Colangelo as Chief ... - Genetic Engineering News

Promedior, Inc. today announced the appointment of Dominick C. Colangelo as Chief Executive Officer and a member of the company’s board of directors. Mr. Colangelo joins Promedior after a nearly 15-year pharmaceutical industry career at Eli Lilly ...

Read more...

---